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Efficient transfer of therapeutic genes into nondividing human cells can be accomplished by inserting the genes into
lentiviruses and infecting the cells with the modified viruses. The most developed lentivirus gene transfer systems are based
on HIV-1, but because of the widespread HIV epidemic, the use of HIV-based vectors for gene therapy may be associated
with a safety risk. In an attempt to find another lentivirus which can transduce human cells and might be safer than HIV-1,
we generated gene transfer constructs based on the sheep lentivirus Visna. Molecular analysis of the constructs in a
transient production system indicated that Visna produced as many mature virus particles as did HIV-1. Moreover, the virus
particles incorporated a heterologous surface protein marker-gene-containing vector RNAs as efficiently as did HIV-1.
However, the Visna virus transduced target cells poorly because of defects in reverse transcription and integration of the
vector. Further modifications must be made to the Visna gene transfer system if the system is to be used in clinical gene
therapy applications. © 2001 Academic Press
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Lentiviruses such as human immunodeficiency virus
(HIV) and feline immunodeficiency virus (FIV) are able to
integrate their genomes into the chromosomes of non-
dividing target cells. Because of this property, which is
not shared by oncoretroviruses like the murine and avian
leukemia viruses, lentiviruses are special candidates for
transduction of nondividing human cells in gene therapy
applications (Buchschacher and Wong-Staal, 2000;
Trono, 2000). To date, five lentiviruses have been used to
generate gene transfer systems: HIV-1 (Miyoshi et al.,
1999; Naldini et al., 1996b), HIV-2 (Arya et al., 1998;
Poeschla et al., 1998a), FIV (Poeschla et al., 1998b),
simian immunodeficiency virus (SIV) (Schnell et al.,
000), and equine infectious anemia virus (EIAV) (Mitro-
hanous et al., 1999; Olsen, 1998). Gene transfer systems
erived from the sheep virus Visna (Sigurdsson et al.,
957; Staskus et al., 1991), the cow virus bovine immu-
odeficiency virus (BIV) (Garvey et al., 1990; Van der
aaten et al., 1972), and the goat virus caprine enceph-
litis virus (CAEV) (Crawford et al., 1980) have not been
eported.
Gene transfer systems based on HIV-1 are by far the
ost developed systems, with documented in vivo trans-
uction of rat brain (Blomer et al., 1997; Naldini et al.,
996a,b), retina (Miyoshi et al., 1997, 1998) muscle, and
iver (Kafri et al., 1997), and mouse trachea (Johnson et
l., 2000). Mouse pancreatic islets were transduced exf
e
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116ivo and transplanted in vivo, with stable expression of
he transgene (Gallichan et al., 1998). In addition, HIV-1-
erived vectors transduced human corneal tissue ex vivo
Wang et al., 2000). Moreover, unstimulated human he-
atopoietic stem cells transduced in vitro have devel-
ped into mature T (Douglas et al., 2000) and B cells
Miyoshi et al., 1999) in in vivo models of lymphocyte
aturation.
Although HIV-1 vectors are the most well studied,
ome authors suggested that HIV-based vectors pose
afety risks for human clinical applications (Buch-
chacher and Wong-Staal, 2000; Trono, 2000). The pos-
ibility has been raised that, if the HIV-1 vector recom-
ines with endogenous human retroviruses (ERVs)
resent in the cells or with exogenous viruses present
uring transient infections, there is a chance of generat-
ng replication-competent HIV-1 or transferring the vector
o other cells in the patient. Such a recombination event
s less likely to occur for nonhuman, or even nonprimate
ectors. In addition, even if the nonprimate lentivirus
ere to become replication-competent, it might not be as
estructive as HIV-1 in humans, although the point has
een debated (Trono, 2000).
We chose to study the ability of Visna virus (Sigurds-
on et al., 1957; Staskus et al., 1991) to mediate gene
ransfer to human cells. A successful lentiviral gene
ransfer system must allow for easy production of high-
iter, replication-defective virus capable of transducing a
arge percentage of nondividing cells in such a way that
he therapeutic gene is expressed at high per-cell levels
or a long period of time (months to years). Toward this
nd, a panel of packaging constructs was generated and
117VISNA VIRUS VECTORSevaluated in a transient expression system for virus
production, maturation, and vesicular stomatitis glyco-
protein (VSV-G) pseudotyping. Similarly, a panel of vec-
tors was generated and evaluated for RNA expression
and encapsidation into virions. Some vector/packaging
construct combinations produced levels of virus similar
to those of an analogous HIV-1 gene transfer system.
However, the Visna virus was impaired in reverse tran-
scription and integration in the target cells, regardless of
the cell type.
RESULTS
Two-plasmid gene transfer system
As a first step in generating Visna virus-based gene
transfer systems, a panel of Visna mutants was gener-
ated (Fig. 1) and tested for virus production, maturation,
and infectivity. The virus was modified in three ways.
First, the 59 LTR U3 region was replaced with the human
cytomegalovirus (CMV) immediate-early promoter (see
constructs VisCa and VisCb, Fig. 1). The junction be-
tween the 39 edge of the CMV promoter and the 59 edge
of the adjoining Visna R region differed in the two con-
structs: in VisCa the DNAs were joined at the respective
transcription start sites, while in VisCb the DNAs were
joined at the respective TATA boxes. Second, approxi-
mately 800 bp were deleted from the interior of the env
gene of VisCaBX in such a way as to retain expression of
the rev gene. Third, a DNA cassette consisting of the
mouse phosphoglycerate kinase (PGK) promoter and the
enhanced green fluorescent protein (eGFP) cDNA was
inserted into the ;800-bp gap in the env gene (see
VisCaPG and VisCbPG, Fig. 1). Similarly, a cassette con-
sisting of the CMV promoter and the eGFP cDNA was
inserted into the same env deletion in the wild-type Visna
plasmid, generating construct VXCG. These eGFP-con-
taining constructs, when expressed in cells coexpress-
ing a suitable viral envelope protein, may form virus
particles capable of transducing fresh cells.
The constructs were then evaluated in a transient
expression system for cytoplasmic gag mRNA levels,
cell-associated Gag protein levels, virion-associated
Gag protein levels, and virion reverse-transcriptase ac-
tivity (Fig. 1). The human kidney carcinoma cell line 293T
was transfected with each construct and, after 2 days,
the cytoplasmic RNA was assayed for Visna gag mRNA
content (Fig. 2A, first five lanes). VisCa and VisCaBX
expressed higher steady-state levels of gag mRNA than
did VXCG and wild-type Visna, indicating that the Visna
LTR is less active than the CMV promoter in 293T cells.
In addition, the virus shed from the transfected cells was
assayed for reverse-transcriptase (RT) activity (Fig. 1,
Experiment 1). VisCa and VisCaBX produced more RT
activity, and hence more viral particles, than did wild-type
Visna, likely because of the elevation in gag mRNA
levels. VisCb and VisCbPG produced only slightly moreparticles than did wild-type Visna. Strangely, the VXCG
preparation contained no RT activity, even though this
construct expressed wild-type levels of gag mRNA (Fig.
2A).
In the same experiment, virus particles were collected
by centrifugation and evaluated by Western blot assay,
using antiserum specific for Visna Gag protein (Fig. 2B,
first seven lanes). In general, the relative amount of
virion-associated Gag protein correlated well with the
relative amount of RT activity (see Fig. 1). Construct
VXCG contained no detectable virion-associated Gag
protein, indicating that the construct must have been
blocked in either Gag protein translation or virion assem-
bly. In addition, all of the constructs’ virus preparations
contained primarily capsid protein instead of Gag
polyprotein, indicating that none of the constructs was
defective in virus maturation. In a separate experiment,
transfected 293T cells were assayed for Visna Gag pro-
tein by Western blot. Wild-type Visna expressed low
levels of Gag protein in the transfected cells, while VisCa
and VisCb expressed high levels (Fig. 1; data not shown).
To determine with more confidence the levels of virus
produced by the constructs, RT assay was performed on
shed virus in three more series of transfections (Fig. 1,
Experiments 2–4). The patterns of virus production ob-
served originally (in Experiment 1) were confirmed: the
CMV-driven constructs produced up to fourfold more
virus than did wild-type Visna, although there was some
variability from experiment to experiment. In addition, the
constructs produced levels of virus comparable to those
produced by a CMV-driven HIV-1 packaging construct
(Douglas et al., 2000) (Fig. 1).
Since VisCaPG and VisCbPG produced high levels of
virus, the viruses shed from transfected 293T cells were
pseudotyped with VSV-G (Burns et al., 1993; Yee et al.,
1994) and tested for their ability to transfer the eGFP
cDNA into new cells. The cell lines used were 293T;
CEMSS, a human lymphoid cell line; and sheep choroid
plexus (SCP) cells, which support wild-type Visna virus
replication (Staskus et al., 1991). Despite the fact that
eGFP was expressed well in the transfected cells, eGFP
was not detected to any significant degree in the infected
cells (Fig. 3). In contrast, a VSV-G-pseudotyped HIV-1
control virus preparation, containing the packaging con-
struct depicted in Fig. 1 and a vector containing an
internal PGK-eGFP cassette (Douglas et al., 2000), trans-
duced the cells readily. The experiment was repeated
several times; the highest transduction efficiency ob-
served was 3%, by VisCbPG (data not shown).
Three-plasmid gene transfer system
Since VisCaPG and VisCbPG were poorly infectious,
the viral genes and eGFP cDNA were separated onto two
plasmids. Four packaging constructs were generated, in
which the Visna gag and pol genes were inserted be-
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119VISNA VIRUS VECTORStween the CMV promoter and the SV40 late polyadenyl-
ation signal (Fig. 1). The 39 325 bp of the Visna leader,
including the major splice donor site (MSD), was re-
tained in constructs VH2 and VH3, although construct
VH3 was deleted in 89 of the 186 bp between the MSD
FIG. 4. Visna vectors and their levels of full-length RNA expressed in t
include the 59 portion of the gag gene, the 39 portion of the env gene,
ajor splice donor site (SD), and the rev 39 splice acceptor site (SA). Ind
romoter (CMV), the murine phosphoglycerate kinase promoter (PGK)
rotein cDNA (eGFP), a small chimeric intron from plasmid pCI (intron fl
f transcriptional initiation are indicated with arrows. Right, measure
orthern assay. In Experiment 1, the amounts of vector RNAs were no
n the autoradiogram. 1/2, low-intensity or undetectable band; 1, ba
amounts of vector RNAs were measured by direct quantitation of the
FIG. 1. Visna packaging constructs and their levels of virus produced.
Indicated regions include the gag, pol, env, tat, and rev genes, the long-
site (MSD), and the tat splice acceptor site (SA). Indicated non-Visna r
the murine phosphoglycerate kinase promoter (PGK), the enhanced gre
(in), a fragment containing the HIV-1 RRE, and an internal ribosome
puromycin N-acetyltransferase cDNA (IRES-puro) (Vara et al., 1986). Rig
for Northern analysis of gag mRNA expression (see Fig. 2a) and reverse
content (see Fig. 2b) was estimated from the intensity of the stained bands. 2
intensity; 11, band of high intensity.and gag; such a deletion might impair encapsidation of
he packaging construct mRNA, by analogy with other
etroviruses (Berkowitz et al., 1996). In contrast, con-
tructs VH1 and VH4 retained minimal leader se-
uences, and were modified by insertion of a small,
ted cell cytoplasm. Left, schematics of Visna vectors; indicated regions
tative Visna packaging signal (c), the long-terminal repeats (LTR), the
non-Visna regions include the human cytomegalovirus immediate-early
ND promoter (Robbins et al., 1997), the enhanced green fluorescent
by SD and SA), and a fragment containing the HIV-1 RRE. The positions
of cytoplasmic, full-length vector RNA expression, as determined by
ly measured, but were estimated based on the intensity of the bands
termediate intensity; 11, band of high intensity. In Experiment 2, the
tivity on the rinsed Northern blot (see Fig. 5).
hematics of virion-producing Visna mutants and packaging constructs.
l repeat (LTR) and rev-response element (RRE), the major splice donor
include the human cytomegalovirus immediate-early promoter (CMV),
rescent protein cDNA (eGFP), a small chimeric intron from plasmid pCI
ite from encephalomyocarditis virus (Jang et al., 1989) linked to the
surements of virus production. Direct measurements were performed
riptase assay (four experiments), while Western analysis of Gag proteinransfec
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120 BERKOWITZ ET AL.chimeric intron upstream of gag. Constructs VH1–VH3
contained all Visna coding regions downstream of pol,
except for approximately 1.4 kb of envelope sequences.
In contrast, packaging construct VH4 contained Visna
sequences terminating 487 bp downstream of pol. Since
VH4 does not contain the rev-response element (RRE)
and the rev gene, the HIV-1 RRE was inserted down-
stream of pol and the HIV-1 rev protein was added in
trans when VH4 was evaluated for expression. In addi-
tion, VH4 was modified by insertion of the puromycin
N-acetyltransferase cDNA (Vara et al., 1986) coupled to
an internal ribosome entry site (IRES) from the encepha-
lomyocarditis virus (ECMV) (Jang et al., 1989), for select-
ing cell lines stably producing the packaging construct.
The four packaging constructs were evaluated in the
transient expression system for steady-state cytoplasmic
gag mRNA levels, cell-associated Gag protein levels,
virion-associated Gag protein levels, and virion reverse-
transcriptase activity as before (Fig. 1). VH2–VH4 ex-
pressed high levels of gag mRNA in the transfected 293T
cells, comparable to that expressed by VisCa (Fig. 2A).
The fact that construct VH4’s gag mRNA level was not
higher than those of the other packaging constructs
suggests that the Visna rev/RRE system functions as
FIG. 2. Expression of packaging construct gag mRNA in transfected
cell cytoplasm (A) and Gag protein in collected virus particles (B). (A)
Cytoplasmic RNA was prepared from 293T cells transfected with the
indicated construct and analyzed for gag mRNA content by Northern
lot assay, using a probe from the Visna pol gene. The positions of the
ag mRNAs are indicated on the right. (B) Virus particles shed from
93T cells transfected with the indicated construct were collected and
valuated for Gag protein content by Western blot assay, using an
ntibody specific for Visna Gag protein. The positions of the Gag
recursor polyprotein (PrGag) and capsid protein (CA) are indicated on
he left.efficiently as the HIV-1 rev/RRE system in 293T cells. VH2
produced large amounts of virus, as detected by RTassay and Gag Western blot (Fig. 1 and Fig. 2B), even
more than that produced by the HIV-1 packaging con-
struct. VH3 produced less virus than did VH2, while VH1
and VH4 produced a lot less virus than did VH2 (Fig. 1
and Fig. 2B). Very little VH1 Gag protein was detected in
the transfected cells, indicating a block in Gag protein
expression (Fig. 1; data not shown). In contrast, VH4
produced high levels of Gag protein in the transfected
cells, suggesting that this construct is blocked in virion
assembly (Fig. 1; data not shown).
A panel of Visna-based vectors was also created, all of
which contained the eGFP cDNA inserted into a deletion
of the viral coding region (Fig. 4). Three different types of
vectors were created: the “VV1” vectors retained short
gag (86-bp) and env (324-bp) segments; the “VV2” vectors
retained longer gag (578-bp) and env (1169-bp) seg-
ments, including the RRE (Tiley and Cullen, 1992); and
the “VV3” vectors contained the longer gag segment, the
short env segment, and a 515-bp HIV-1 env segment
containing the HIV-1 RRE. Each of the vector types con-
tained the PGK promoter linked to eGFP, either with or
without a small chimeric intron between the two seg-
ments. In addition, a seventh vector (VV2-MG) was
generated, using vector type “VV2” and containing the
myeloid proliferative sarcoma virus (MPSV, or “MND”)
promoter (Robbins et al., 1997) linked to eGFP. Each of
the seven vectors contained a chimeric 59 LTR in which
CMV promoter sequences, up to the TATA box, were
linked to the Visna LTR sequences following the TATA
box.
The vectors were first analyzed for their steady-state
expression levels in human cells. Each of the vectors
was introduced into 293T cells along with packaging
construct VH3 and, 2 days later, the cytoplasmic RNA
was assayed for vector RNA content. First, vectors VV1-
PG, VV1-PIG, and VV2-PG were analyzed, using a probe
that detects both full-length RNAs (driven by the chimeric
59 LTR) and internal RNAs (driven by the PGK promoter).
Although the amounts of the vector RNAs were not quan-
titated, visual inspection of the autoradiogram indicated
that the three vectors expressed different amounts of the
different RNAs (Fig. 4 and data not shown). VV1-PG
expressed high levels of internal RNA and low levels of
full-length RNA, while VV1-PIG expressed extremely high
levels of internal RNA but no detectable full-length RNA.
VV2-PG produced intermediate levels of full-length RNA
and internal RNA, as well as high levels of spliced RNA
[i.e., between the MSD and the rev splice acceptor (SA)
site].
The experiment was repeated, using vectors VV2-PG,
VV2-PIG, VV3-PG, and VV3-PIG and a probe that detects
only LTR-driven, not internal, RNAs (Fig. 5). As before, the
VV2-PG vector was observed to express intermediate-to-
high levels of full-length RNA (“F”) and 1-kb spliced RNA
(“S”; Fig. 5). The VV3-PG vector, which lacks the Visna rev
splice acceptor site, expressed only the full-length vector
t
f ect fres
e cells
121VISNA VIRUS VECTORSRNA but not the spliced RNA (Fig. 5). The amount of
full-length VV3-PG RNA was quantitated and found to be
comparable to the amount of full-length VV2-PG RNA.
This result indicates either that the Visna rev protein
functions efficiently with the HIV-1 RRE, in contrast to a
previous study (Tiley and Cullen, 1992), or that the rev/
RRE system is not required for the cytoplasmic expres-
sion of the full-length vector RNAs. In contrast, the VV2-
PIG and VV3-PIG vectors, containing a chimeric intron
between the PGK promoter and eGFP, expressed low
levels of full-length vector RNA (Fig. 5 and Fig. 4). How-
ever, both vectors expressed high levels of a 2 to 2.5-kb
RNA species (“S9”) generated by splicing between the
MSD and the chimeric intron SA. This splicing event also
predominated over splicing between the MSD and the
rev SA, since the 1-kb spliced RNA was not detected. The
2 to 2.5-kb S9 RNA occasionally underwent further splic-
ing, presumably between cryptic splice donor sites in
eGFP or Visna env and the rev SA, since other RNA
species (Fig. 5, 1.9 and 1.6 kb in first lane) were present
for vector VV2-PIG but not for VV3-PIG, which lacks the
rev SA.
To determine the ability of the Visna vectors to trans-
FIG. 3. Transduction of 293T and CEMSS cells by the Visna 2-plasm
hree-plasmid HIV-1 system (see text). Two days later, the virus-contain
low cytometry (left column). The virus-containing media was used to inf
xpression by flow cytometry (right column). The percentage of eGFP1duce human cells, virus collected from 293T cells triple-
transfected with VH2, VSV-G, and either VV2-PG, VV3-PG,or VV2-MG was analyzed by RT assay and exposed to
fresh 293T cells. Each vector expressed high levels of
eGFP in the transfected cells (Fig. 6). Three days later,
em. 293T cells were cotransfected with VSV-G and VisCbPG or with a
dia was collected and the cells were analyzed for GFP expression by
h 293T and CEMSS cells; 3 days later, the cells were analyzed for GFP
is indicated in each histogram.
FIG. 5. Expression of Visna vectors in transfected cell cytoplasm.
PolyA1 RNA was purified from cytoplasmic RNA prepared from 293T
cells transfected with the indicated vector and analyzed for vector
mRNA content by Northern blot assay, using a probe from the Visnaid syst
ing meleader. The positions of the full-length (F), spliced (S), and alternatively
spliced (S9) bands are indicated on the right.
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122 BERKOWITZ ET AL.the infected cells were analyzed for eGFP expression by
flow cytometry. The VV2-PG virus produced 496 pg of RT
activity and transduced 4% of the cells, the VV3-PG virus
produced 779 pg of RT activity and transduced 1% of the
cells, and the VV2-MG virus produced 630 pg of RT
activity and transduced 5% of the cells. In contrast, an
HIV-1 control virus consisting of the packaging construct
depicted in Fig. 1 and a vector containing an internal
MND-eGFP cassette produced 1289 pg of RT activity and
transduced 100% of the cells. The transduced cells were
kept in culture and analyzed 2 weeks postinfection: 7% of
the VV2-MG-infected cells were eGFP1. Thus, while the
fficiency of Visna transduction was low, the expression
f the transgene was stable. A VV2-PG virus preparation
as also used to transduce SCP cells; however, eGFP
FIG. 6. Transduction of 293T cells by the Visna 3-plasmid system.
293T cells were transfected with VSV-G, VH2, and the indicated Visna
vector or with a three-plasmid HIV-1 system. Two days later, the
virus-containing media was collected and the cells were analyzed for
GFP expression by flow cytometry (left column). The virus-containing
media was used to infect fresh 293T cells; 3 days later, the cells were
analyzed for GFP expression by flow cytometry (right column). The
percentage of eGFP1 cells is indicated in each histogram.as not detected in the SCP cells 3 days postinfection
data not shown).The reason for low transduction efficiencies
The inability of the Visna virus preparations to trans-
duce cells readily was investigated. First, virus prepara-
tions were analyzed for VSV-G content and encapsidated
vector RNA content. To determine whether the Visna
virus particles were pseudotyped with the VSV-G protein,
293T cells were cotransfected with VH3 and a plasmid
encoding VSV-G, then virions were collected and ana-
lyzed for VSV-G content by immunoblot assay (Fig. 7). To
provide a relative estimate of the efficiency of VSV-G
incorporation, virus shed from 293T cells cotransfected
with VSV-G and the HIV-1 packaging construct depicted
in Fig. 1 was normalized by RT assay and analyzed
concurrently. The amount of VSV-G protein contained on
the Visna particles was not less than the amount on the
HIV-1 particles (Fig. 7).
To determine how well the full-length vector RNAs
were encapsidated by Visna virions, 293T cells were
triple-transfected with vector VV2-MG, packaging con-
struct VH2, and the VSV-G plasmid. RNA was prepared
from the collected virions and analyzed for vector RNA
content, using an eGFP-specific probe that detects both
full-length and internal vector RNAs (Fig. 8). To provide a
relative estimate of the efficiency of Visna vector RNA
encapsidation, a control system consisting of the HIV-1
packaging construct depicted in Fig. 1 and the HIV-1
MND-eGFP vector (see above) was analyzed side by
side with the Visna system (Fig. 8 and Table 1). Since the
full-length HIV-1 vector RNA is similar in size to the
full-length Visna vector RNA and the two RNAs are de-
tected with the same probe, the Northern analysis reli-
FIG. 7. Incorporation of VSV-G on Visna virus particles. Virus particles
shed from 293T cells transfected with the indicated constructs were
collected, normalized by RT assay, and evaluated for vesicular stoma-
titis virus glycoprotein (VSV-G) content by Western blot assay, using a
monoclonal antibody specific for VSV-G. The position of VSV-G is
indicated on the right. The two lanes on the left contain, instead of virus
particles, lysates from mock- or VSV-G-transfected 293T cells.
o
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123VISNA VIRUS VECTORSably indicates the relative amounts of the two RNAs.
Moreover, since the Visna and HIV-1 RT proteins pos-
sess similar specific activities in the RT assay (data not
shown), the vector RNA content can be normalized by the
T
Comparison of Visna and HIV-1 Efficiencies of R
Virus
Northern analysis of RNA packaging
Viral
RNAa
(cpm)
RT
assayb
(pg)
RNA
per
virionc
Cytoplasmic
RNAa (cpm)
Packaging
efficiencyd
Vector
plasmide
(fg)
Visna 2001 560 3.57 4735 7.5 3
HIV-1 1455 464 3.14 8188 3.8 1
a The amount of full-length vector RNA in the virus RNA and cytoplasm
which hybridized to the RNA on the Northern blot (see Fig. 8).
b The amount of virus was inferred from the amount of reverse trans
c The relative amount of full-length vector RNA per virion was calcula
preparation by the amount of virus.
d The relative packaging efficiency was calculated by dividing the re
vector RNA detected in the polyA1 cytoplasmic RNA preparation.
e The lowest dilution of the indicated DNA sources containing detect
vector-specific primers.
f The relative amount of unintegrated vector DNA synthesized in the
f cell lysate containing detectable vector DNA and factoring in the ef
NA).
g The relative amount of integrated vector DNA contained within the in
f genomic DNA containing detectable vector DNA and factoring in the
NA).
h The percentage of transduced cells was determined by flow cytom
FIG. 8. Encapsidation of a Visna vector. Cytoplasmic polyA1 RNA
was prepared from 293T cells triple-transfected 2 days earlier with
Visna vector VV2-MG, packaging construct VH2, and VSV-G, or with
similar HIV-1 gene transfer constructs. In addition, RNA was prepared
from virus collected from the transfected cells. The RNA preparations
were analyzed for vector RNA content by Northern blot assay, using a
probe from the eGFP cDNA. The full-length vector RNA is the upper
band (3 kb for the HIV-1 vector, 3.3 kb for the Visna vector). In addition,
eGFP is contained on internal HIV-1 (1.1-kb) and Visna (2.3-kb) mRNAs,
which are not encapsidated.i The relative amount of integrated vector per transduced cell was calculate
f transduced cells.amount of virus. The Visna virus preparation contained
38% more full-length vector RNA than did the HIV-1 virus
preparation, but also contained 21% more virus particles;
as a result, the amount of full-length vector RNA per
particle was 14% higher for Visna than for HIV-1. Since
the transfected cell cytoplasm contained 72% more full-
length HIV-1 vector RNA than Visna vector RNA, the
full-length Visna vector RNA was encapsidated with 97%
higher efficiency than that of the full-length HIV-1 vector
RNA.
Since the Visna virus preparations were not deficient
in VSV-G or vector RNA content, the low transduction
efficiencies were reasoned to be the result of deficien-
cies occurring during the infection process. To determine
whether Visna was impaired in reverse transcription in
the infected cells, the Visna (VV2-MG) and HIV-1 virus
preparations analyzed in Fig. 8 were treated with DNase
I, normalized for full-length vector RNA content using the
information from the Northern blot assay, and used to
infect fresh 293T cells. Twenty hours later, a portion of
the cells was lysed and serial dilutions of the lysates
were analyzed for vector DNA content by polymerase
chain reaction (PCR) analysis (Fig. 9, Table 1). The PCR
primers were located in the R region and near the gag
start codon, to amplify DNA synthesized only when the
process of reverse transcription was nearly completed.
When tested on dilutions of the HIV-1 and VV2-MG plas-
ckaging, Reverse Transcription, and Integration
CR analysis of reverse transcription and integration
d Unintegrated
vector f
Genomic
DNAe
Integrated
vectorg
Percentage
transductionh
Integrated
vector per
transduced
cell i
1 100 ng 1 0.74 1
30 100 pg 300 76 3
yA1 RNA preparations was inferred from the amount of labeled probe,
e detected in the virus preparation.
ividing the amount of full-length vector RNA detected in the virus RNA
mount of full-length vector RNA per virion by the amount of full-length
ctor DNA was determined by PCR amplification of the dilutions, using
d cells 20 h postinfection was inferred by inverting the lowest dilution
of the PCR primers (i.e., multiplying by the lowest dilution of plasmid
cells 2 weeks postinfection was inferred by inverting the lowest dilution
cy of the PCR primers (i.e., multiplying by the lowest dilution of plasmid
nalysis of eGFP expression 2 weeks postinfection.ABLE 1
NA Pa
P
Infecte
cellse
3
0.03
ic pol
criptas
ted by d
lative a
able ve
infecte
ficiency
fected
efficien
etric a
d by dividing the amount of integrated vector DNA by the percentage
cells.
ncies
124 BERKOWITZ ET AL.mids, the Visna primers were threefold less efficient than
the HIV-1 primers (Fig. 9D). When tested on the HIV-1
virus-infected cells, the HIV-1 primers detected vector
DNA in the PCR reaction containing 0.03 cell-equivalents
but not in the reaction containing 0.01 cell-equivalents
(Fig. 9B), indicating that approximately 30 copies of vec-
tor DNA were synthesized per cell. Visna vector DNA
was detected in the PCR reaction containing 3 cell-
equivalents but not in the reaction containing 1 cell-
equivalent (Fig. 9C), indicating that approximately one
copy of vector DNA was synthesized per cell (factoring in
the threefold inefficiency of the Visna primers). Since the
same amount of virion-associated vector RNA was
added to the cells, the Visna virus was roughly 30-fold
defective, relative to HIV-1, in reverse transcription in the
293T cells (Table 1). PCR amplification of endogenous
b-globin DNA confirmed that the HIV-1- and Visna-in-
fected cell lysates contained similar cell equivalents per
unit volume (Fig. 9C).
The cells were kept in culture and analyzed for eGFP
expression 2 weeks postinfection. Some 76% of the HIV-
1-infected cells were eGFP1, while only 0.74% of the
Visna-infected cells were eGFP1 (data not shown). Since
the 100-fold difference in eGFP expression was greater
than the 30-fold difference in reverse-transcription effi-
ciency, the possibility arose that the Visna virus was
impaired in another step during infection, e.g., vector
integration. To determine whether the Visna virus was
impaired in vector integration, the Visna- and HIV-1-
infected cells were analyzed for integrated vector con-
tent by PCR assay, using the same primers as before
(Fig. 10, Table 1). HIV-1 vector DNA was detected in
genomic DNA 1000-fold more diluted than was Visna
FIG. 9. Reverse transcription of a Visna vector in infected 293T cells.
RNA content by Northern blot assay (see Fig. 8) and used to infect 293
were subjected to PCR amplification of vector DNA. (A) HIV-1-infected
HIV-1- and Visna-infected cells. (D) HIV-1 and Visna PCR primer efficievector DNA; factoring in the threefold inefficiency of the
Visna primers, the data indicate that the cells containedapproximately 300-fold less integrated Visna vector DNA
than HIV-1 vector DNA. Thus, in addition to the 30-fold
impairment in reverse transcription, Visna was 10-fold
impaired in vector integration, relative to HIV-1 (Table 1).
Moreover, since the 300-fold excess of HIV-1 vector DNA
was distributed among 100-fold more transduced (i.e.,
eGFP-expressing) cells, each transduced cell, on aver-
age, likely contained approximately threefold more cop-
ies of the HIV-1 vector than of the Visna vector. Indeed,
the HIV-1-infected eGFP1 cells exhibited a three- to four-
fold higher mean-channel fluorescence (i.e., average flu-
orescence per cell) than did the Visna-infected eGFP1
cells (data not shown). Moreover, the HIV-1-transduced
cells were found to contain 5–10 copies of the vector per
cell (S. Tamaki, submitted).
To determine whether the defects of the Visna virus
were the result of its production in human cells, the
VV2-MG Visna virus was produced in sheep choroid
plexus (SCP) cells, which are permissive for Visna virus
replication (Staskus et al., 1991). Because of the low
transfection efficiency of SCP cells, relatively little virus
was shed from the cells: only 14 pg of RT activity for the
Visna virus and 2 pg of RT activity for the HIV-1 virus. The
viruses were exposed to fresh SCP and 293T cells, after
which the cells were cultured for 2 days and analyzed for
eGFP expression. The VV2-MG virus transduced 1% of
the 293T cells and none of the SCP cells, while the HIV-1
virus transduced 4% of the 293T cells and 1% of the SCP
cells (data not shown). Since the Visna virus produced in
SCP cells transduced 293T and SCP cells inefficiently,
compared to that of HIV-1 virus production, the inefficient
reverse transcription and integration of the Visna virus
I-treated Visna and HIV-1 viruses were normalized for full-length vector
. Twenty hours later, the cells were lysed and threefold serial dilutions
(B) Visna-infected cells. (C) b-Globin sequences were amplified from
were determined using serial dilutions of vector plasmid DNA.DNase
T cellsproduced in 293T cells must not be the result of produc-
tion in 293T cells per se.
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In this study we examined in detail the ability of
Visna virus to serve as a gene transfer system for the
infection of human cells. We found that Visna-derived
packaging constructs could produce virus in amounts
that were the same as or more than those produced by
a comparable HIV-1-derived packaging construct; as
with the HIV-1 virus, the Visna virus underwent effi-
cient maturation and was efficiently pseudotyped by
VSV-G. We also found that Visna-derived vectors could
be encapsidated within the virus particles with an
efficiency that is equal or superior to that of a compa-
rable HIV-1 vector. Thus, the Visna gene transfer sys-
tem produced as much potentially infectious virus as
did the HIV-1 system.
However, the undiluted VSV-G-pseudotyped virus
produced by the Visna constructs inefficiently trans-
duced human cells because of a 30-fold defect in
reverse transcription and a 10-fold defect in vector
integration. The defect was not the result of the human
cells per se, since the Visna virus also poorly trans-
duced sheep choroid plexus (SCP) cells, which sup-
port wild-type Visna virus replication. The low trans-
duction efficiencies were also noted when the Visna
FIG. 10. Integration of a Visna vector in infected 293T cells. Dnase
content (see Fig. 8) and used to infect 293T cells. Two weeks later, gen
were subjected to PCR amplification of vector sequences (top panel) or
Visna- or HIV-1-infected cells used in the PCR reaction is indicated
amplification of 1 mg genomic DNA from mock-infected 293T cells; p,
ndicates the position of the amplified vector DNA.virus was produced in SCP cells, indicating that the
defect was not the result of improper viral assembly in
a
ccertain cell types, as noted for vif mutants of HIV-1
(Gabuzda et al., 1992). Instead, it is likely that the poor
infectivity of the Visna virus resulted from generalized
inefficiencies in reverse transcription and integration
in the infected cells, regardless of cell type. The re-
verse-transcription deficit was not the result of a de-
fect in reverse transcriptase per se, since the enzyme
exhibited comparable specific activity to the HIV-1
reverse transcriptase in an in vitro assay. Moreover,
ransfection of the SCP cells with the wild-type Visna
onstruct, which was shown by sequence analysis to
e identical to the published clone (Staskus et al.,
991), yielded syncytium formation after 10 days of
ulture, indicating that the virus is indeed infectious
unpublished observations).
Other nonhuman lentiviruses were reported to trans-
uce human cells with efficiencies approaching those of
IV-1 (Berkowitz et al., submitted; Mitrophanous et al.,
999; Olsen, 1998; Poeschla et al., 1998; Schnell et al.,
000), so it is surprising that the Visna vectors were
oorly infectious. It is possible that the observed defects
n reverse transcription and integration result from pecu-
iarities of the Visna vectors instead of the viral enzymes.
t would be interesting to determine whether the defects
d Visna and HIV-1 viruses were normalized by full-length vector RNA
NA was isolated from the cells and 10-fold serial dilutions of the DNA
in sequences (bottom panel). The amount of genomic DNA (in ng) from
each lane. Abbreviations: m, molecular-weight marker DNA; c, PCR
mplification of 1 pg vector plasmid DNA. The arrow in the top panelI-treate
omic D
b-glob
abovere also observed for the other infectious molecular
lone of Visna, kv72 (Andresson et al., 1993). If the de-
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126 BERKOWITZ ET AL.fects are intrinsic to Visna in general, the virus would
require further modification to generate a successful
gene transfer system.
MATERIALS AND METHODS
Plasmids
All restriction endonucleases were obtained from
Roche Molecular Biochemicals (Indianapolis, IN) unless
otherwise noted. Plasmid pCI was obtained from Pro-
mega (Madison, WI). Plasmid pCIGL contains the vesic-
ular stomatitis virus glycoprotein (VSV-G) cDNA (Burns et
al., 1993; Yee et al., 1994) in the pCI polylinker, down-
tream of the human cytomegalovirus (CMV) immediate-
arly promoter and chimeric intron and upstream of the
imian virus 40 (SV40) late polyadenylation signal. Plas-
id pCrev, containing the HIV-1 rev cDNA under control
f the CMV promoter, was described previously (Malim
t al., 1988). Plasmid pVis, containing the wild-type Visna
lone LV1-1KS1 (Staskus et al., 1991), was modified by
conventional subcloning techniques, to generate pack-
aging constructs and vectors as follows. First, plasmids
pVAS and pVSX, containing short polylinkers in place of
much of the Visna coding region, were generated by di-
gesting pVis with ApaI and SgrI or SpeI and XbaI and
igating the small fragment to polylinkers created by anneal-
ng oligonucleotides VAS5 (59-CCTCGAGGCGGCCGCG-
ATGCTAGCCGCGGCA-39) and VAS3 (59-CCGGTGC-
GCGGCTAGCATGCGCGGCCGCCTCGAGGGGCC-39) or
VSX5 (59-CTAGTCTCGAGGCGGCCGCGCATGCTAGCCGC-
GGT-39) and VSX3 (59-CTAGACCGCGGCTAGCATGCGCG-
GCCGCCTCGAGA-39).
The CMV immediate-early enhancer/promoter was
used to replace the Visna promoter in the 59 LTR in
plasmids pVAS and pVSX, with the junction either at the two
TATA boxes or at the two transcription start sites. First, the
upstream CMV region was subjected to PCR amplification
with primers CB5 (59-CGGGATCCCGTAGTTATTAATAGTA-
ATCAATTACGG-39) and either CV3A (59-TCTGCTTTTC-
CCACGGTTCACTAAACGAGCTCT-39) or CV3B (59-GCG-
GCTTATATAGACCTCCCACCGTACACGCCT-39), while the
downstream Visna region was subjected to PCR amplifica-
tion with primers Vnru3 (59-CACAAGAGCAACACTGGTA-
AGG-39) and either CV5A (59-TTAGTGAACCGTGGGAAAAG-
CAGAGTGCTTTGG-39) or CV5B (59-CGGTGGGAGGTC-
TATATAAGCCGCTTGCTAGCTGG-39). Second, the CMV-
and Visna-amplified products were mixed and subjected to
amplification using primers CB5 and VN3. The two final
products were digested with BamHI and NruI and ligated to
plasmids pVAS and VSX, previously digested with BamHI
and NruI, generating plasmids pVASCa, pVASCb, pVSXCa,
and pVSXCb. The BamHI–SpeI fragment, containing the
chimeric LTR, of plasmids pVSXCa and pVSXCb was then
used to replace the corresponding fragment of pVis, gen-
erating plasmids pVisCa and pVisCb.
Plasmids pVisCa and pVisCb were digested withBsu36I (New England Biolabs, Beverly, MA) and XbaI to
delete interior env sequences; the large fragment was
then ligated to a fragment from plasmid pHPEGFP
(Douglas et al., 2000) containing the mouse phospho-
glycerate kinase (PGK) promoter (Adra et al., 1987) linked
to the enhanced green fluorescent protein (eGFP) cDNA
(Promega), generating plasmid pVisCaPG and pVis-
CbPG. In addition, the pVisCa fragment was recircular-
ized to produce plasmid pVisCaBX. Plasmid pVis was
similarly digested with Bsu36I and XbaI and ligated to
the CMV promoter linked to eGFP, generating plasmid
pVXCG. Plasmids pVASCb and pVSXCb were linearized
by digestion of the SphI site in the polylinker and ligated
to the PGK–eGFP fragment, generating plasmids
pVV1-PG and pVV2-PG, or to a similar fragment also
containing the pCI intron, generating plasmids pVV1-PIG
and pVV2-PIG. Plasmids pVV2-PG and pVV2-PIG were
then digested with NsiI and SgrAI to delete most of the
env sequences and ligated to a 500-bp fragment con-
taining the HIV-1 rev-response element (RRE). Plasmid
pVV2-MG was generated by digesting pVSXCb at the
XhoI site in the polylinker and ligating the linearized
fragment to an NdeI/NotI-digested fragment from plas-
mid pHSMPSVegfp containing the MND promoter (Rob-
bins et al., 1997) linked to the eGFP cDNA. Plasmid
pHSMPSVegfp is a variant of plasmid pHSMPSVlacZ (S.
Tamaki, submitted) in which the b-galactosidase cDNA
was replaced with the eGFP cDNA.
Plasmid pVH1 was generated by sequential insertion
of two pVis segments into the pCI polylinker using stan-
dard techniques: a 6-kb NruI–HincII fragment containing
the gag, pol, vif, and tat genes, as well as the first coding
exon of the rev gene; and a 1.2-kb XbaI–BstEII segment
containing the RRE and the second coding exon of the
rev gene. Plasmid pVH2 was generated in a similar
fashion, but the large fragment contained an additional
222 bp of leader sequences, including the major splice
donor site, and was inserted in place of the pCI chimeric
intron. pVH3 is identical to pVH2 but contains a 89-bp
deletion between the NruI and NheI sites upstream of
gag. Plasmid pVH4 was constructed by insertion of a
5.1-kb NruI–CelII fragment, containing the gag and pol
genes, but not the vif or tat genes, into the pCI polylinker.
In addition, plasmid pVH4 possesses a fragment of HIV-1
containing the RRE, as well as an internal ribosome entry
site (IRES) from encephalomyocarditis virus (Jang et al.,
1989) linked to the puromycin N-acetyltransferase cDNA
(Vara et al., 1986).
Virus production
293T cells were obtained from Gary Nolan (Stanford
University, Palo Alto, CA). Sheep choroid plexus (SCP)
cells were obtained from the American Tissue Type Col-
lection (ATCC; Manassas, VA). Both cell lines were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
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127VISNA VIRUS VECTORSsupplemented with 10% FCS. 293T cells (4–10 3 106) or
SCP cells (1–2 3 106) were seeded into 10-cm dishes
overnight and transfected the next day with 20–30 mg
plasmid DNA by the calcium phosphate method (Clon-
tech, Palo Alto, CA). Typically, 20 mg of the vector, 10 mg
of the packaging construct, and 3 mg of the envelope
plasmid were used. In cases where the HIV-1 rev protein
was required, 4 mg of plasmid pCrev was added. After
4–72 h the cells or the virus-containing medium was
ollected and analyzed in a variety of ways (see below).
o assess the efficiency of transfection, a portion of the
ransfected cells was removed from the plate by expo-
ure to EDTA or trypsin and analyzed for eGFP expres-
ion by flow cytometry using a FACScan (Becton Dickin-
on Biosciences, San Jose, CA). To measure the amount
f virus shed into the medium, the medium was cleared
f cellular debris by low-speed centrifugation, then 10 ml
was lysed and analyzed for RT activity using a commer-
cial kit (Roche Molecular Biochemicals).
Analysis of RNA levels
Cells were lysed and cytoplasmic RNA was prepared
using a commercial kit (Qiagen, Valencia, CA); in some
instances, polyA1 RNA was isolated by a commerical kit
(Qiagen). Virus-containing medium was collected, sub-
jected to mid-speed centrifugation to remove cellular
debris, and then subjected to high-speed centrifugation
(50,000 g 90 min at 4°C) to pellet the virus particles. The
viral pellet was lysed and the viral RNA was prepared
using a commercial kit (Qiagen). A fixed amount of
polyA1 RNA (usually 200 ng) or viral RNA (usually one-
hird of the RNA prep, not quantitated) was subjected to
% agarose gel electrophoresis and transferred to a
ylon filter (Bio-Rad, Hercules, CA). The filter was ex-
osed to 40 3 106 cpm of a DNA fragment random-
primed with 32P-dCTP using a commercial kit (Ambion,
ustin, TX), then washed and analyzed for bound probe
ith a phoshporimager (Molecular Dynamics, Sunnyvale,
A). The DNA fragments included a Visna 1.1-kb pol
fragment, a 0.4-kb Visna leader fragment, a 0.5-kb Visna
env/U3 fragment, and a 0.8-kb eGFP fragment.
Analysis of protein levels
Cells were lysed on ice for 1 h in a buffer containing
% NP-40, 150 mM NaCl, 10 mM Tris–HCl, pH 7.4, 1
M EDTA, and Pefabloc protease inhibitor (Roche
olecular Biochemicals). The lysate was subjected to
entrifugation at 8000 g 20 min at 4°C to remove
recipitated proteins and other debris. Alternatively,
irus-containing medium was collected, subjected to
rief centrifugation to remove cellular debris, and then
ubjected to high-speed centrifugation (50,000 g 90
min at 4°C) to collect the virus particles. The viral
pellet was lysed directly in SDS–PAGE sample buffer
(Novex, San Diego, CA). A fixed amount of cell or virallysate was subjected to acrylamide gel electrophore-
sis and transferred to a nitrocellulose filter. The filter
was exposed to goat serum specific for Visna Gag
protein (a gift of J. Clements), then to horseradish
peroxidase (HRP)-conjugated rabbit anti-goat Ig anti-
body (Zymed, South San Francisco, CA), then to the
HRP substrate OPD (Sigma, St. Louis, MO). Prestained
molecular weight standards (Bio-Rad) were used to
determine the approximate molecular weight of the
labeled Visna Gag bands. For the VSV-G Western blot,
the filter was exposed to mouse anti-VSV-G monoclo-
nal antibody (Sigma) and then to the HRP-conjugated
goat anti-mouse Ig antibody (Zymed) before the OPD
reaction.
Analysis of transduction
To transduce cells, 3 ml of the virus-containing me-
dium previously cleared of cellular debris was added
to fresh 293T or SCP cells in six-well dishes (2 3 105
SCP, 5 3 105 293T seeded per well the previous day).
Protamine sulfate (Sigma) and HEPES buffer was
added to the wells at a final concentration of 4 mg/ml
and 10 mM, respectively, and the dishes were sub-
jected to centrifugation (“spinoculation”) at 3000 rpm
for 2–3 h at 32–37°C. Spinoculation was used since
the procedure brings more virions to the cells’ mem-
branes than would normally occur without centrifuga-
tion. After spinoculation, the dishes were placed back
in the incubator for 30–60 min, then virus-containing
medium was removed and fresh medium was added to
the wells. Two to 3 days postspinoculation, a portion of
the cells was removed from the plate by exposure to
EDTA and analyzed for eGFP expression by flow cy-
tometry using a FACScan (Becton Dickinson Bio-
sciences).
Analysis of reverse-transcribed vector DNA
Sixteen to 24 h after spinoculation, a portion of the
cells was lysed, then serial dilutions of the lysate were
subjected to PCR to amplify a segment of the vector DNA
synthesized near the end of reverse transcription. The
primers used were VR (59-GGAGAGCTCGAAGGAAA-
GAGTC-39), in the R region, and Vgag (59-AGGAG-
CAGCGTCCGTGGTCCC-39), upstream of the gag start
codon. For HIV-1-infected control cells, the analogous
primers were M667 (59-GGCTAACTAGGGAACCCACTG-
39) and M661 (59-CCTGCGTCGAGAGAGCTCCTCTGG-39).
The reaction products were then subjected to agarose
gel electrophoresis and ethidium bromide staining. The
amount of vector DNA is inferred from the dilution in
which the amplified band can no longer be detected
and/or the relative intensities of the amplified bands, as
detected by visual inspection. The efficiencies of the
primer sets were determined using dilutions of the vector
plasmids pHS-MPSVegfp and pVV2-MG. In addition, the
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128 BERKOWITZ ET AL.cell-equivalents of the lysates were determined using
b-globin primers LA1 and LA2 (Plavec et al., 1996).
Analysis of integrated vector DNA levels
Genomic DNA was isolated from the cells 2 weeks
after spinoculation using a commercial kit (Qiagen). Se-
rial dilutions of the genomic DNA were subjected to PCR
amplification using Visna primers VR and Vgag and HIV-1
primers M667 and M661 (see above). The reaction prod-
ucts were then subjected to agarose gel electrophoresis
and ethidium bromide staining. The amount of vector
DNA is inferred from the dilution in which the amplified
band can no longer be detected and/or the relative in-
tensities of the amplified bands, as detected by visual
inspection. The cell-equivalents of the DNA preparations
were determined using b-globin primers LA1 and LA2
Plavec et al., 1996).
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